Abattis Terminates $600,000 Private Placement

VANCOUVER, March 11, 2013 /CNW/ - Abattis Bioceuticals Corp. ("Abattis" or the "Company") (CNSX: FLU) (OTC: ATTBF), announces that it will not be proceeding with its $600,000 non-brokered private placement as previously announced in its Press Release dated February 12, 2013 as it is canvassing other avenues of financing through strategic relationships to prevent any dilution for its shareholders.

About Abattis Bioceuticals Corp.

Abattis Bioceuticals Corp. is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of producing, licensing and marketing proprietary ingredients and products containing standardized phytochemicals for sale in Pharmaceutical, Nutraceutical, Cosmetic and Animal Nutrition markets. The company also has a deep pipeline of proprietary products ready for sale in high growth areas of Functional Foods and Supplements business. For more information, visit the Company's website at www.abattis.com.


"Mike Withrow"   
Mike Withrow
President & CEO

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Abattis Bioceuticals Corp.

For further information:

Mike Withrow 
P: 778.908.6650

Organization Profile

Abattis Bioceuticals Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890